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ABSTRACT 
NOD-like receptor 3 (NLRP3) plays critical roles in the initiation of inflammasome-mediated inflammation in 
microglia, thus becomes an important therapeutic target of Alzheimer’s disease (AD). Dexmedetomidine (Dex), a 
new type of clinical anesthetic agent, shows anti-inflammatory properties and inhibits postoperative cognitive 
dysfunction in AD patients. The present study was aimed to investigate effect of Dex on NLRP3 activity in acti-
vated microglia and reveal the underlying mechanisms. The human microglia clone 3 (HMC3) cells were exposed 
to 100 ng/ml LPS and 5 mM ATP, in the presence and absence of doses of Dex. Data from ELISA and Western 
blot assays showed that Dex abrogated the promoting effects of LPS/ATP on the release of pro-inflammatory 
cytokines including IL-1 and IL-18 in the cell medium and the expression of NLRP3 and its downstream target 
caspase-1 in HMC3 cells. Furthermore, the present study found that exposure of HMC3 cells to LPS/ATP in-
creased nuclear protein levels of transcription factor c-Fos, but treatment with Dex reversed the increase in c-Fos, 
as indicated by Western blot and immunofluorescence measures. Luciferase reported assay revealed that c-Fos can 
bind to the promoter region of NLRP3 gene and positively regulate the expression. These results suggest that Dex 
inhibiting c-Fos nuclear protein levels promoted by LPS/ATP blocks the up-regulation of NLRP3. This suggestion 
is supported by co-immunoprecipitation and PCR studies, in which Dex decreased the amount of c-Fos that binds 
to NLRP3 under the stimulation of LPS/ATP. The present study revealed that Dex inhibits inflammation in mi-
croglia cells under stimulation of LPS and ATP by c-Fos/NLRP3/caspase-1 cascades, which adds new understand-
ing of the anti-inflammatory mechanism of Dex. 
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INTRODUCTION 
Alzheimer’s disease (AD) is a prevalent 
neurodegenerative disease, which involves 
progressive memory loss, cognitive impair-
ment, behavioral deficits and dementia (Val-
lée and Lecarpentier, 2016). Microglial cells 
are the resident immuno-competent cells of 
the central nervous system (CNS), responsi-
ble for sensing any perturbation in the CNS 
and orchestrating the immune response (Ude-
ochu et al., 2016). In addition, they actively 
participate in CNS wiring and modulation of 
neuronal activities (Schafer et al., 2012). 
However, uncontrolled or chronic activation 
of microglia is closely correlated to the path-
ogenesis of AD (Ramirez et al., 2017). A local 
activation of microglial cells is consistently 
detected in the brains of AD patients 
(Ramirez et al., 2017). The release of pro-in-
flammatory mediators from activated micro-
glia is potentially harmful and can cause cel-
lular damage. There is evidence indicating 
that microglial activation is associated with 
deposition of amyloid-beta (Aβ), formation of 
amyloid plaques (senile plaques) and neurofi-
brillary tangles (Ramirez et al., 2017).  
NOD-like receptors (NLRs), a class of cy-
tosolic sensors or receptors, play critical roles 
in the initiation of inflammasome-mediated 
neuroinflammation in microglia (Freeman 
and Ting, 2016). NLRs can detect and re-
sponse to pathogen-associated molecular pat-
terns (PAMPs), which are linked to bacterial, 
viral and fungal, as well as damage-associated 
molecular patterns (DAMPs) that are pro-
duced during tissue and cell damages (Free-
man and Ting, 2016). NLRP3 is one of the 
most extensively studied classes of NLRs. 
Activated NLRP3 triggers the cleavage of 
pro-caspase-1 into its active and mature form 
caspase-1. Caspase-1 then induces a second-
ary cascade of events associated to releases of 
pro-inflammatory cytokines such as IL-1 
and IL-18 cytokines (Saresella et al., 2016). 
These cytokines are known to cause the pro-
liferation and activation of neuroinflamma-
tory cells such as microglia and astrocytes. As 
NLRP3 represents a critical mediator of neu-
roinflammation, it becomes an important ther-
apeutic target of AD and other neurodegener-
ative diseases (Saresella et al., 2016).  
Converging evidence suggests that ad-
ministration of general anesthesia (e.g. isoflu-
rane-mediated anesthesia) increases the risk 
of AD. An increased incidence of AD in older 
patients undergoing general anesthesia has 
been found by scholars studying the relation-
ship between anesthesia and AD (Xie et al., 
2006; Planel et al., 2009). In addition, isoflu-
rane anesthesia is associated to increased 
postoperative cognitive dysfunction (POCD) 
in AD patients and aged people (Zhang et al., 
2017a). Dexmedetomidine (Dex), a specific 
agonist of α2-adrenoceptor, has been used as 
a new type of clinical anesthetic agent espe-
cially for calmness of tracheal intubation and 
mechanical ventilation in surgical patients un-
der general anesthesia (Liu et al., 2017). Dex 
is one of the few anesthetics that show inhib-
itory effect on POCD and neuroprotective ac-
tions against brain ischemia (Zhou et al., 
2016; Liu et al., 2017). Furthermore, an 
emerging literature shows that Dex inhibits 
NLRP3 inflammasome activation, and conse-
quently alleviates hyperoxia-induced acute 
lung injury in an in vivo model, which sug-
gests that Dex also has anti-inflammatory 
properties (Zhang et al., 2017b). The present 
study investigated whether Dex has the capac-
ity to inhibit NLRP3 activity in activated mi-
croglia to reveal the potential neuroprotective 
effect against AD.  
 
MATERIALS AND METHODS 
Cell culture and treatments 
The human microglia clone 3 cell line 
(HMC3) was purchased from American Type 
Culture Collection (ATCC, Rockville, MD, 
USA). HMC3 cells were initially produced by 
transfecting human embryonic brain-derived 
macrophages with the large T antigen of the 
simian virus 40. HMC3 cells were cultured in 
Eagle’s Minimum Essential Media  (Thermo 
Fisher Scientific, Shanghai, China) supple-
mented with 10 % fetal calf serum (Sigma-
Aldrich, St. Louis, MO, USA) and 100 units/ml 
(U/ml) penicillin/streptomycin (Invitrogen, 
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Carlsbad, CA, USA), and incubated in a hu-
midified atmosphere (5 % CO2) at 37 °C. 
Cells were plated in 24-well plates at 2 × 105 
cells/well at least for 24 h before treatment 
with pharmacological substances.  
HMC3 cells were activated by culturing in 
the medium with lipopolysaccharide (LPS, 
100 ng/ml, Sigma-Aldrich) for 24 h and with 
adenosine triphosphate (ATP, 5 mM, Sigma-
Aldrich) for additional 30 min. To determine 
the anti-inflammatory effects of Dex (Sigma-
Aldrich) in HMC3 cells, these cells were 
treated with various concentrations of Dex (0, 
0.1, 1, or 10 µM) when exposing to LPS/ATP. 
ELISA assay was performed to evaluate con-
centrations of pro-inflammatory cytokines, 
including IL-1 and IL-18, in the media.  
 
Cell viability 
Cell viability was analyzed by 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. HMC3 cells were 
seeded into each well of a 96-well micro-
plate. After treatments, MTT (Beyotime Insti-
tute of Biotechnology, Nanjing, China) solu-
tion was added to the cells with a final con-
centration of 1 mg/mL and the mixture was 
allowed to incubate at 37 °C for about 4 h. The 
supernatant was removed, and then the pellets 
were dissolved in dimethyl sulfoxide (Be-
yotime Institute of Biotechnology). The ab-
sorbance was measured by spectrophotome-
try at 570 nm using an Elx-800uv reader (Bio-
Tek Instruments, Winooski, VT, USA).  
 
ELISA assay 
Culture supernatants were collected and 
stored at −20 °C until analysis. The concen-
trations of IL-1 and IL-18 cytokines in cell 
culture supernatants were measured using 
ELISA kits (R&D Systems, Minneapolis, 
MN, USA) according to the manufacturer’s 
instructions. 
 
Western blot analysis 
Cellular whole protein and nuclear protein 
were extracted respectively using the Protein 
Extraction Kit (Sigma, St Louis, MO, USA) 
and NE-PER Nuclear Extraction Reagents 
(Thermo Scientific, Rockford, IL, USA) accord-
ing to the manufacturers’ protocols. The pro-
tein concentration in the supernatant fluid of 
the lysate was measured by the BCA protein 
assay (Pierce, Rockfold, IL, USA). Equal 
amounts of protein (20 μg) in each well were 
loaded for electrophoresis in 12 % sodium do-
decyl sulfate-polyacrylamide gels, and then 
gels were transferred to polyvinylidene fluo-
ride microporous membranes (PVDF; Milli-
pore, Bedford, MA, USA). Membranes con-
taining the transferred proteins were blocked 
with 5 % skim milk in TBS containing 0.1 % 
Tween-20 (TBST) for 2 hours at room tem-
perature. The membranes were hybridized 
with antibodies against NLRP3 (Dilution 
1:500, ab214185, Abcam, Shanghai, China), 
caspase-1 (Dilution 1:800, ab14367, Abcam), 
c-Fos (Dilution 1:500, ab134122, Abcam), 
Histone (Dilution 1:1000, sc-56616, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) 
and GAPDH (Dilution 1:1000, sc-365062, 
Santa Cruz Biotechnology) at 4 °C overnight. 
The primary antibodies were visualized by 
adding secondary biotin-conjugated antibod-
ies followed by an avidin/biotin/peroxidase 
complex (Vectastain ABC Elite kit; Vector 
Laboratories Inc, Burlingame, CA, USA) and 
substrate (Vector Nova RED, Vectastain).  
 
c-Fos overexpression and knockdown  
An open-reading frame clone of Homo sa-
piens c-fos gene was inserted into the en-
hanced green fluorescent protein plasmid-C1 
(pEGFP-C1) vector (GenePharma Co., Ltd) 
to construct over-expression vectors of c-Fos. 
The c-Fos vectors were transfected into 
HMC3 cells using Lipofectamine TM 2000 
(Invitrogen, Carlsbad, CA, USA), according 
to the manufacturer’s instructions. HMC3 
cells that were transfected with the empty 
vectors were used as the control. Small inter-
fering RNA (siRNA) oligonucleotides against 
c-Fos (siRNA-c-Fos) and the corresponding 
scrambled control oligonucleotides were syn-
thesized from Genephama Biotech (Shanghai, 
China). For c-Fos knockdown, 60 nM siRNA-
c-Fos was transfected into HMC3 cells using 
X-tremeGENE siRNA Transfection Reagent 
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(Roche, Germany) according to the manufac-
turer’s protocol. 
 
Luciferase reporter assay 
The promoter region of NLRP3 gene was 
cloned and inserted into pGL3-basic vector 
(Promega, Madison, Wisconsin, USA) at site 
between XhoI and SacI to form pGL3-
NLRP3-promter construct. Within 48 h of 
passage and more than 80% confluent, HMC3 
cells were transfected with pGL3-NLRP3-
promter constructs, pGL3-NLRP3-promter 
constructs + c-Fos vectors, pGL3-basic vec-
tors, or pGL3-promoter constructs using 
Lipofectamine TM 2000 (Invitrogen) in 24-
well plates. Each well included 1.5×105 cells, 
1 mg indicated constructs, 0.04 mg internal 
control vector pRL-TK, 2 ml Lipofectamine 
TM 2000 and 500 ml culture media without 
serum and antibiotics. All cells were analyzed 
for dual-luciferase reporter activity 48 h after 
completion of the transfection procedure, us-
ing a Sirius luminometer (Berthold Detection 
System GmbH, Pforzheim, Germany).  
 
Immunofluorescence (IF) assay  
The HMC3 cells were fixed with 4 % par-
aformaldehyde for 15 min and blocked with 
PBS containing 0.3 % Triton X-100/5 % BSA 
(w/v) for 1 h at room temperature. The cells 
were immunostained with c-Fos antibody 
(Dilution 1:800, Abcam) at 37 °C for 2 h, and 
then incubated with secondary antibody 
(1:1000) and DAPI (0.3 μM). Fluorescent in-
tensity was evaluated using a Zeiss Axi-
oskop2 Microscope and Axiovision v4.8.1 
software (Carl Zeiss MicroImaging, Inc. Wei-
mar, Germany).  
 
Co-immunoprecipitation (Co-IP) and PCR 
assays 
Nucleoprotein in HMC3 cells was ex-
tracted with a CelLytic™ NuCLEAR™ Ex-
traction Kit (Sigma-Aldrich; Merck KGaA, 
Germany) and incubated c-Fos primary anti-
body (1:500 dilution; Santa Cruz Biotechnol-
ogy, Inc.) at 4 °C for 60 min with gentle mix-
ing. Subsequently, 20 µl Protein A/G Plus-
Agarose beads (Thermo Fisher Scientific, 
Inc.) were added, followed by incubation at 
4 °C overnight. The mixture was centrifuged 
at 500 x g for 5 min at 4 °C. The supernatant 
was discarded and the Co-IP products were 
washed three times with PBS. After the final 
wash, the precipitates were re-suspended in 
40 μl sample buffer and detected by PCR to 
quantify the NLRP3 gene expression.  
PCR was performed using the iQ5 Multi-
color Real-Time PCR Detection System (Bio-
Rad Laboratories Inc., Hercules, CA, USA) 
with SYBR Premix Ex Taq II (Takara). The 
PCR primer sequences for NLRP3 and 
GAPDH were as follows: NLRP3, (F)5’-
GCTGGTCTTGAATTCCTCA-3’ and (R) 
5’-GGCACACGGATGAGTCTTT-3’; 
GAPDH, (F) 5’-TACTAGCGGTTTTAC-
GGGCG-3’ and (R) 5’- TCGAACAGGAG-
GAGCAGAGAGCGA-3’. A melting curve 
analysis of the amplified products was per-
formed at the end of each PCR cycle. The 
comparative C(T) method was used to quan-
tify the expression of NLRP3 using GAPDH 
as the normalization control. 
 
Statistical analysis 
Data were expressed as mean ± SD 
(range) for the parametric variables, analyzed 
using SAS9.0 software (SAS Institute, USA). 
Analysis of variance (ANOVA) was per-
formed to compare the difference between 
multiple groups using t test. P value <0.05 
was regarded as significant. 
 
RESULTS 
Dex inhibits inflammatory responses of 
HMC3 cells induced by LPS/ATP 
In the present study, microglia HMC3 
cells were activated by culturing in the me-
dium containing LPS and ATP. Activated 
HMC3 cells showed decreased cell viability 
(p<0.05, Figure 1A) and increased release of 
inflammatory factors, including IL-1 
(p<0.01, Figure 1B) and IL-18 (p<0.05), com-
pared with non-activated cells. To understand 
the anti-inflammatory effect of Dex in HMC3 
cells, these cells were treated with various 
concentrations of Dex (0, 0.1, 1, or 10 µM) 
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when exposing to LPS/ATP. The inhibited 
cell viability was notably restored by 10 µM 
Dex (p<0.05 vs. LPS/ATP group, Figure 1A), 
but not by 0.1 and 1 µM Dex. Adding 1 
(p<0.05 vs. LPS/ATP group, Figure 1B) and 
10 µM Dex (p<0.01 vs. LPS/ATP group) to 
cells decreased the increase of IL-1 release 
by LPS/ATP. The increase in IL-18 release by 
LPS/ATP was also decreased by 10 µM Dex 
(p<0.05 vs. LPS/ATP group).  
 
 
 
Figure 1: Dex inhibits inflammatory responses of HMC3 cells induced by LPS/ATP 
HMC3 cells were exposed to 100 ng/ml LPS and 5 mM ATP, in the presence and absence of doses of 
Dex. The cells were then subjected to the measurement of cell viability (A). ELISA (B) and Western blot 
assays (C) assessed the concentrations of pro-inflammatory cytokines including IL-1 and IL-18 in the 
cell medium and the expression of NLRP3 and its downstream target caspase-1 in the cells, respec-
tively. *P<0.05, **P<0.01, #P<0.05 and ##P<0.01vs. control; &P<0.05, &&P<0.01, $P<0.05 and $$P<0.01vs. 
LPS/ATP group. Dex: Dexmedetomidine 
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NLRP3/caspase-1 cascades mediate the 
production and release of inflammatory fac-
tors, such as IL-1 and IL-18, following the 
stimulation of LPS/ATP (Schafer et al., 
2012). Western blot assay revealed that treat-
ment with LPS/ATP indeed increased NLRP3 
expression in HMC3 cells (p<0.01 Figure 
1C), however the increase in NLRP3 expres-
sion was reduced by 0.1 (p<0.05), 1 (p<0.01) 
and 10 µM Dex (p<0.01). Activated NLRP3 
triggers the cleavage of pro-caspase-1 into its 
active and mature form caspase-1 (Schafer et 
al., 2012). Protein level of non-cleaved 
caspase-1 in HMC3 cells was decreased by 
treatment with LPS/ATP (p<0.01), but 
cleaved caspase-1 was dramatically increased 
(p<0.01 Figure 1C). The decreased protein 
level of non-cleaved caspase-1 was restored 
by 10 µM Dex (p<0.01 vs. LPS/ATP group, 
Figure 1C), but not by 0.1 and 1 µM Dex. The 
increase in protein level of cleaved caspase-1 
was reduced by 0.1 (p<0.05), 1 (p<0.05) and 
10 µM Dex (p<0.01). These data suggest that 
the anti-inflammatory effect of Dex is associ-
ated with the inhibition of NLRP3/caspase-1 
cascades.  
 
c-Fos mediates the inhibitory effect of Dex 
on NLRP3 
There is evidence indicating that various 
biological effects of Dex are associated with 
its modulating transcription factor c-Fos 
(Zhang et al., 2013; Xiong et al., 2016). The 
present study found that nuclear protein levels 
of c-Fos was dose-dependently decreased by 
Dex from 0.1 (p<0.05) to 10 µM (p<0.01) in 
HMC3 cells that were not exposed to 
LPS/ATP (Figure 2A). To determine that c-
Fos is involved in the regulation of NLRP3 
gene expression, we performed luciferase re-
port assay, in which a pGL3-NLRP3-promter 
reporter was constructed by inserting the pro-
moter region of NLRP3 gene into pGL3-basic 
vector. Results showed that the pGL3-pro-
moter reporters, which are provided by the de-
tection kits to be used as positive control, had 
notably higher luciferase activity than pGL3-
basic vectors (p<0.001, Figure 2B). Similarly, 
the pGL3-NLRP3-promter reporter also 
showed higher luciferase activity than pGL3-
basic vectors (p<0.01). Co-transfection with 
c-Fos expression vectors further increased lu-
ciferase activity of pGL3-NLRP3-promter re-
porters (p<0.01 vs. pGL3-NLRP3-promter). 
Results of luciferase report assay indicate that 
c-Fos serves as the transcription factor posi-
tively regulating NLRP3 gene expression. 
Thus, Dex decreasing nuclear protein levels 
of c-Fos likely inhibits NLRP3 gene expres-
sion.  
 
 
Figure 2: c-Fos mediates the inhibitory effect 
of Dex on NLRP3 
HMC3 cells were treated with doses of Dex. West-
ern blot detected nuclear protein levels of c-Fos in 
the HMC3 cells (A). In luciferase reporter assay, 
HMC3 cells were transfected with pGL3-NLRP3-
promter constructs, pGL3-NLRP3-promter con-
structs + c-Fos vectors, pGL3-basic vectors, or 
pGL3-promoter constructs using Lipofectamine 
TM 2000 (B). *P<0.05, **P<0.01 and 
***P<0.001vs. control. Dex: Dexmedetomidine 
 
 
Dex decreases c-Fos nuclear protein levels 
and subsequently inhibits NLRP3 expres-
sion under the stimulation of LPS/ATP 
Treatment with 10 µM Dex decreased c-
Fos nuclear protein levels in HMC3 cells that 
was not exposed to LPS/ATP (p<0.01, Figure 
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3A). Exposure to LPS/ATP caused remarka-
ble increase of c-Fos nuclear protein levels in 
HMC3 cells. However, knockdown of c-Fos 
(p<0.001 vs. LPS/ATP group) or treatment 
with 10 µM Dex dramatically decreased c-
Fos nuclear protein levels under LPS/ATP 
stimulation (p<0.01 vs. LPS/ATP group). 
NLRP3 protein level in HMC3 cells was de-
creased after treatment with 10 µM Dex alone 
(p<0.01). LPS/ATP stimulation increased 
NLRP3 protein levels in HMC3 cells. How-
ever, LPS/ATP induced increase in NLRP3 
protein levels was reversed by c-Fos knock-
down (p<0.01 vs. LPS/ATP group) and Dex 
treatment (p<0.01 vs. LPS/ATP group). We 
also performed IF assay to detect c-Fos nu-
clear protein levels in HMC3 cells. Dex treat-
ment decreased c-Fos nuclear protein levels in 
HMC3 cells without LPS/ATP stimulation 
(p<0.05 vs. control, Figure 3B). LPS/ATP 
stimulation increased c-Fos nuclear protein 
levels, but the increase was abrogated by c-
Fos knockdown or Dex treatment (p<0.01 vs. 
LPS/ATP group). Co-IP was performed to de-
tect the amount of c-Fos binding to the pro-
moter of NLRP3 gene. Data from PCR assay 
showed decreased expression of NLRP3 gene 
following Dex treatment (p<0.05, Figure 3C), 
which suggests decreased binding of c-Fos to 
the NLRP3 gene. Treatment with LPS/ATP 
increased expression of NLRP3 gene 
(p<0.05), suggesting increased of c-Fos to the 
NLRP3 gene. c-Fos knockdown (p<0.01 vs. 
LPS/ATP group) and Dex treatment (p<0.05 
vs. LPS/ATP group) abolished the c-Fos ex-
pression increase by LPS/ATP. 
 
Figure 3: Dex inhibits c-Fos/NLRP3 cascades in microglia cells under the stimulation of LPS/ATP 
HMC3 cells were treated with LPS/ATP compounds and Dex alone or in combination. c-Fos was 
knocked down in a proportion of HMC3 cells treated with LPS/ATP compounds. Both Western blot (A) 
and IF assays (B) detected c-Fos nuclear protein levels and NLRP3 protein levels in the HMC3 cells. 
Co-IP and PCR assays (C) were performed to detect the amount of c-Fos binding to the promoter of 
NLRP3 gene. *P<0.05, **P<0.01, and ***P<0.001 vs. control; #P<0.05, ##P<0.01 and ###P<0.01 vs. 
LPS/ATP group.
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DISCUSSION 
The present study provided convincing 
evidences that Dex plays an anti-inflamma-
tory role in human microglia cells under 
LPS/ATP stimulation. Chronic abnormal in-
flammation is correlated with amyloidosis, 
neurodegeneration, and memory loss in AD 
(Schafer et al., 2012). Inflammation in AD 
can be induced by exogenous pathogens and 
sterile endogenous agents (Ishida et al., 
2017). LPS, an endotoxin isolated from gram-
negative bacteria, can induce inflammatory 
responses, amyloidogenesis and neuronal 
damage, thus accelerating the progression of 
a neurodegenerative disease (Choi et al., 
2017). LPS has been widely used to conduct 
an experimental model of microglia activa-
tion (Choi et al., 2017). LPS administered into 
brain induces microglia activation, and results 
in accumulation of Aβs in both the cerebral 
cortex and hippocampus (Sheng et al., 2013). 
LPS increases amyloid precursor protein ex-
pression and β- and γ-secretase activities, 
which promotes amyloidogenesis (Sheng et 
al., 2013). Extracellular ATP can act as a uni-
versal danger-associated molecular pattern 
with several known mechanisms for immune 
cell activation (Gilbert et al., 2016; Gaikwad 
et al., 2017). It has been demonstrated that 
ATP, alone or in combination with LPS, acti-
vates microglia and astrocytes and induces a 
neuroinflammatory response in the central 
nervous system (Gaikwad et al., 2017; Lim et 
al., 2017). In the present study, co-treatment 
with LPS and ATP stimulated the release of 
IL-1β and IL-18 from human microglia cells. 
IL-1β and IL-18 have been linked with the pa-
thology of AD. AD patients exhibit increased 
levels of IL-1β and IL-18 in the serum and 
brain compared with the health controls 
(Singhal et al., 2014; Demirci et al., 2017). 
The increased generation of these proinflam-
matory cytokines causes microglial and astro-
gliosis activation and promotes the release of 
other pro-inflammatory molecules, resulting 
in unrestrained neuroinfammation (Singhal et 
al., 2014). However, appropriate doses of Dex 
significantly reduced release of IL-1β and IL-
18 from human microglia cells under 
LPS/ATP stimulation, suggesting the anti-in-
flammatory effect in microglia cells.  
Inflammasomes are responsible for the 
maturation of pro-inflammatory cytokines 
such as IL-1β and IL-18 (Schafer et al., 2012). 
NLRP3 plays important roles in the initiation 
of inflammasome-mediated neuroinflamma-
tion in microglia (Schafer et al., 2012). NLRs 
promote the assembly of a large multiprotein 
complex called the inflammasome and trigger 
the cleavage of pro-caspase-1 into its active 
and mature form caspase-1. The precursor 
molecules of IL-1β and IL-18 can be cleaved 
into their mature and active forms by caspase-
1 protease (Pan et al., 2016). LPS and ATP 
stimulation has been shown to activate 
NLRP3/caspase-1 cascades and consequently 
increases IL-1β and IL-18 production in mac-
rophage cells (Gurung et al., 2015). Inhibition 
of NLRP3 decreases the production of IL-1β 
and IL-18 both in LPS/ATP-stimulated BV2 
microglia in vitro and spinal cord from EAE 
mice in vivo (Jiang et al., 2017; Yang et al., 
2018). Caspase-1 inhibition decreased IL-1β 
production in BV2 microglial cells that are 
activated by LPS-treated RAW264.7 macro-
phages (Pan et al., 2016). This evidence indi-
cates that NLRP3/caspase-1 cascades medi-
ates the increased production of IL-1β and IL-
18 in immune cells under LPS/ATP-stimula-
tion. Exposure to LPS/ATP also increased 
NLRP3 and caspase-1 expression in human 
microglia HMC3 cells. However, treatment 
with Dex abrogated the increase in NLRP3 
and caspase-1 expression. Previous reports 
manifest that the effects of Dex against LPS-
induced inflammatory response is related to 
the inhibition of NF-κB (Liu et al., 2016). It 
has been acknowledged that LPS interacts 
with Toll-like receptors and subsequently ac-
tivates NF-κB. NF-κB regulates expression of 
a majority of inflammatory factors, such as 
IL-1β and IL-18 (Liu et al., 2016). But, ini-
tially generated IL-1β and IL-18 are inacti-
vated and rely on further processing by 
NLRP3/caspase-1 cascades for their matura-
tion (Pan et al., 2016). The present study adds 
novel evidence that Dex also suppresses 
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NLRP3/caspase-1 cascades to inhibit inflam-
matory response induced by LPS/ATP. 
There is evidence indicating that various 
biological effects of Dex is associated with its 
modulating transcription factor c-Fos. Previ-
ous study found that intrathecal administra-
tion of Dex reduces the formalin-induced 
paw-flinching behaviour in rats, which is due 
to the analgesic effects of Dex via a α2-recep-
tor dependent manner as well as the inhibition 
of c-Fos activation (Zhang et al., 2013). Inhi-
bition of c-Fos activation by Dex alleviates 
postoperative cognitive dysfunction by ab-
normal neuron excitation in aged rats as well 
(Xiong et al., 2016). The present study found 
that c-Fos nuclear protein levels in HMC3 
cells were notably increased in HMC3 cells 
under the stimulation of LPS/ATP, but treat-
ment with Dex abolished the increase in c-Fos 
nuclear protein levels, as indicated by both 
Western blot and IF assays. Luciferase report 
assay further revealed that c-Fos can bind to 
the promoter region of NLRP3 gene and pos-
itively regulate its expression. Thus, it was 
suggested that Dex inhibiting c-Fos nuclear 
protein levels promoted by LPS/ATP blocks 
the up-regulation of NLRP3. This suggestion 
is supported by our Co-IP and PCR studies, in 
which Dex decreased the amount of c-Fos that 
binds to NLRP3 under the stimulation of 
LPS/ATP.  
The present study revealed that Dex inhib-
its inflammation in microglia cells under 
stimulation of LPS and ATP by c-Fos/ 
NLRP3/caspase-1 cascades, which adds new 
understanding of the anti-inflammatory 
mechanism of Dex. The outcome thus re-
vealed the potential neuroprotective effect of 
Dex against AD.  
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